Prostacyclin: Its pathogenic role in essential hypertension and the class effect of ACE inhibitors on prostaglandin metabolism

Blood Pressure

Volumn 8, Issue 5-6, 1999, Pages 279-284

  Rodríguez García, José Luis ^a   Villa, Eduardo ^b   Serrano, Manuel ^a   Gallardo, Julia ^a   García Robles, Rafael ^b  

^a HOSPITAL GENERAL LA MANCHA CENTRO   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

6 keto prostaglandin F1 ; Angiotensin converting enzyme inhibitors; Prostacyclin

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; PROSTACYCLIN; RAMIPRIL;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; PROSTAGLANDIN RELEASE;

EID: 18144444054     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370599439490     Document Type: Article

References (23)

1. Mombouli JV, Vanhoute PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 1999; 31: 61-74.
2. Ruschitzka F, Corti R, Noll G, Lüscher TF. A rationale for treatment of endothelial dysfunction in hypertension. J Hypertens 1999; 17 Suppl: 25-35.
3. Dzau VJ. Vascular renin-angiotensin system in hypertension. New insights into the mechanism of action of angiotensin converting enzyme inhibitors. Am J Med 1988; 84: 4-8.
4. Mombouli JV, Vanhoutte PM. Heterogeneity of endothelium-dependent vasodilator effects of angiotensin-converting enzyme inhibitors: role of bradykinin generation during ACE inhibition. J Cardiovasc Pharmacol 1992; 20 (Suppl 9): S74-82.
5. Mitchell MD. A sensitive radioimmunoassay for 6-keto-prostaglandin F1-alpha: preliminary observations on circulating concentrations. Prostaglandins Med 1978; 1: 13-21.
6. Forsterman U, Neufang B. Elimination from the circulation of cats of 6-keto-prostaglandin El compared with prostaglandins E2 and I2. J Pharm Pharmacol 1983; 35: 724-8.
7. Somova LI, Mufunda JJ. Renin-angiotensin-aldosterone system and thromboxane A2/prostacyclin in normotensive and hypertensive black Zimbabweans. Ethn Dis 1992; 2: 27-34.
8. Chen LS, Ito T, Ogawa K, et al. Plasma concentrations of 6-keto-prostaglandin F1 alpha, thromboxane B2 and platelet aggregation in patients with essential hypertension. Jpn Heart J 1984; 25: 1001-9.
9. Falerdeau P, Martineau A. In vivo production of prostaglandin 12 in Dahl-sensitive and salt-resistant rats. Hypertension 1983; 5: 701-5.
10. Numaguchi Y, Harada M, Osanai H, et al. Altered gene expression of prostacyclin synthase and prostacyclin receptor in the thoracic aorta of spontaneously hypertensive rats. Cardiovasc Res 1999; 41: 682-8.
11. Lemne CE, Vesterqvist O, Egberg N, et al. Platelet activation and prostacyclin release in essential hypertension. Prostaglandins 1992; 44: 219-25.
12. Minuz P, Barrow SE, Cockcroft JR, Ritter JM. Prostacyclin and thromboxane biosynthesis in mild essential hypertension. Hypertension 1990; 15: 469-74.
13. Ritter JM, Brett SE, Woods JD, Benjamin N, Stratton PD, Barrow SE. Prostacyclin biosynthesis in essential hypertension before and during treatment. J Hum Hypertens 1996; 10: 37-42.
14. Vanhoutte PM, Boulanger CM, Illiano SC, et al. Endothelium-dependent effects of converting-enzyme inhibitors. J Cardiovasc Pharmacol 1993; 2 (Suppl 5): S10-6.
15. Carbonell LF, Carretero OA, Stewart JM, Scicli G. Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension. Hypertension 1988; 11: 239-43.
16. Luque M, Martin P, Martell N, et al. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens 1996; 14: 799-805.
17. Cushman DW, Wang FL, Fung WC, et al. Differentiation of angiotensin enzyme inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 1989; 2: 294-306.
18. Murohara T, Horowitz JR, Silver M, et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998; 97: 99-107.
19. Gerber JG, Franca G, Byyny RL, LoVerde M, Nies AS. The hypotensive action of captopril and enalapril is not prostacyclin dependent. Clin Pharmacol Ther 1993; 54: 523-32.
20. Guivernau M, Armijo F, Rosas R. Role of sulfhydryl groups in the stimulatory effect of captopril on vascular prostacyclin synthesis. Eur J Pharmacol 1991; 30: 1-6.
21. Nakagawa M, Kobaya SH, Sawada S, et al. Comparative studies of angiotensin converting enzyme inhibitors with and without the SH-radical. Am J Hypertens 1991; 4: 54-5.
22. van Gilst WH, Scholtens E, de Graeff PA, et al. Differential influences of angiotensin converting-enzyme inhibitors on the coronary circulation. Circulation 1988; 77: 24-9.
23. Weisser K, Schloos J. Measurements of serum ACE activity in vitro after administration of enalapril in man cannot reflect inhibition of the enzyme in vivo. Methods Find Exp Clin Pharmacol 1993; 15: 413-8.